Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EPS without NRI Growth Rate was 28.80% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 13.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Bolt Biotherapeutics was 28.80% per year. The lowest was -31.90% per year. And the median was -2.70% per year.
Bolt Biotherapeutics (FRA:6LP0) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Bolt Biotherapeutics 3-Year EPS without NRI Growth Rate Related Terms
FRA:6LP0 vs NCNA, CELZ, CURX: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Bolt Biotherapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bolt Biotherapeutics 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Bolt Biotherapeutics's 3-Year EPS without NRI Growth Rate falls into.
Bolt Biotherapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 28.80% mean?
Bolt Biotherapeutics (FRA:6LP0) has a 3-Year EPS without NRI Growth Rate of 28.80% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bolt Biotherapeutics and its competitors. According to the industry distribution chart, Bolt Biotherapeutics ranks #403 out of 1155 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Bolt Biotherapeutics' 3-Year EPS without NRI Growth Rate too high?
Bolt Biotherapeutics' current 3-Year EPS without NRI Growth Rate is 28.80%. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.00. Bolt Biotherapeutics' value of 28.80% is 80% above this industry median. Based on the distribution chart, Bolt Biotherapeutics ranks #403 out of 1155 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' 3-Year EPS without NRI Growth Rate compare to NCNA and CELZ?
According to the Biotechnology industry distribution chart, Bolt Biotherapeutics ranks #403 out of 1155 companies for 3-Year EPS without NRI Growth Rate. This puts Bolt Biotherapeutics in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.00. Bolt Biotherapeutics' value of 28.80% is 80% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.00, based on 1,155 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bolt Biotherapeutics's current 3-Year EPS without NRI Growth Rate of 28.80% is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Bolt Biotherapeutics and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bolt Biotherapeutics's current 3-Year EPS without NRI Growth Rate is 28.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Bolt Biotherapeutics (FRA:6LP0) has a current 3-Year EPS without NRI Growth Rate of 28.80%. The stock's GF Value™ is €8.22, compared to a current price of €5.18 — trading 37% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 28.80% and 80% above the Biotechnology industry median of 16.00. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Bolt Biotherapeutics (FRA:6LP0), the current 3-Year EPS without NRI Growth Rate is 28.80% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bolt Biotherapeutics (FRA:6LP0) Overvalued in 2026?
Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued.
The current stock price of €5.18 is trading 37% below its estimated GF Value™ of €8.22.
Key valuation signals for FRA:6LP0:
3-Year EPS without NRI Growth Rate: 28.80%
GF Value™: €8.22 vs. price of €5.18 (37% below fair value)
Industry Position: 80% above the Biotechnology median (#403 of 1155)
No single metric tells the full story. See the FRA:6LP0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score
Get the complete analysis for FRA:6LP0
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6LP0 has been successfully added to your 
